| Home | Search Abstracts | Browse Sessions | Program Committee | Conference Webcasts | Contact Us |
|
Session 27
Oral Abstracts Pharmacology and New Antiretroviral Agents Wednesday, 10 am - 12:45 pm Room 3000 |
| Moderators | Dominic Schols Rega Inst for Med Res, Katholieke Univ, Leuven, Belgium Jose F Rodriguez Univ of Puerto Rico Sch of Med, San Juan, USA |
| 10:00 am 131 | Stop Study: After Discontinuation of Efavirenz, Plasma Concentrations May Persist for 2 Weeks or Longer S Taylor*1, S Allen2, S Fidler3, D White1, S Gibbons4, J Fox3, J Clarke3, J Weber3, P Cane5, A Wade2, E Smit5, and D Back4 1Birmingham Heartlands Hosp. and Univ. of Birmingham, UK; 2Coventry and Warwickshire Hosp., UK; 3Imperial Coll. London & St. Marys Hosp., UK; 4Univ. of Liverpool, UK; and 5HPA, Birmingham Heartlands Hosp., UK |
| 10:15 am 132 | Relationships between Efavirenz Pharmacokinetics, Side Effects, Drug Discontinuation, Virologic Response, and Race: Results from ACTG A5095/A5097s H Ribaudo*1, D Clifford2, R Gulick3, C Shikuma4, K Klingman5, S Snyder6, and E Acosta7 1Harvard Sch. of Publ. Hlth., Boston, MA, USA; 2Washington Univ., St. Louis, MO, USA; 3Cornell Univ., New York, NY, USA; 4Univ. of Hawaii, Honolulu, USA; 5DAIDS, NIAID, NIH, DHHS, Bethesda, MD, USA; 6Social and Sci. Systems, Inc., Silver Spring, MD, USA; and 7Univ. of Alabama at Birmingham, USA |
| 10:30 am 133 | A Common CYP2B6 Variant Is Associated with Efavirenz Pharmacokinetics and Central Nervous System Side Effects: AACTG Study NWCS214 D Haas*1, H Ribaudo2, R Kim1, C Tierney2, G Wilkinson1, R Gulick3, D Clifford4, T Hulgan1, and E Acosta5 1Vanderbilt Univ., Nashville, TN, USA; 2Statistical and Data Analysis Ctr. (SDAC), Harvard Sch. of Publ. Hlth., Boston, MA, USA; 3Weill Med. Coll. of Cornell Univ., New York, NY, USA; 4Washington Univ., St. Louis, MO, USA; and 5Univ. of Alabama at Birmingham, USA |
| 10:45 am 134 | Lopinavir Inhibitory Quotient Predicts Virologic Response in Highly Antiretroviral-experienced Patients Receiving High-dose Lopinavir/Ritonavir R Bertz*1, J Li1, M King1, D Kempf1, D Podzamczer2, C Flexner3, C Katlama4, D V Havlir5, S Letendre6, J Eron7, L Weiss8, J Gatell9, A Simon4, K Robinson1, and S Brun1 1Abbott Labs., Abbott Park, IL, USA; 2Hosp. de Bellvitge, Barcelona, Spain; 3Johns Hopkins Univ. Sch. of Med., Baltimore, MD, USA; 4Hosp. de la Pitie-Salpetriere, Paris, France; 5Univ. of California, San Francisco, USA; 6Univ. of California, San Diego, USA; 7Univ. of North Carolina at Chapel Hill, USA; 8Hosp. Europeen George Pompidou, Paris, France; and 9Hosp. Clin., Barcelona, Spain |
| 11:00 am 135 | Unexpected Complexity in Nuclear Receptor Activation by HIV Protease Inhibitors and Induction of CYP Enzymes and Transporters C Marzolini*, R G Tirona, W Lee, G Gervasini, R H Ho, B F Leake, and R B Kim Vanderbilt Univ. Sch. of Med., Nashville, TN, USA |
| 11:15 am 136LB | Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients With HCV/HIV Co-infection: Final Results of a Randomized Clinical Study J-M Gries*1, F J Torriani2, M Rodriguez-Torres3, V Soriano4, M J Borucki5, P Piliero6, E Lissen7, M Sulkowski8, K Wang1, D Dieterich9, and D Back10 1Roche, Nutley, NJ, USA; 2Univ. of California, San Diego, La Jolla, USA; 3Fndn. de Investigacion de Diego, Santurce, Puerto Rico; 4Inst. de Salud Carlos III, Madrid, Spain; 5Univ. of Texas Hlth. Ctr., Tyler, USA; 6Albany Med. Coll., NY, USA; 7Virgen del Rocío Univ. Hosp., Seville, Spain; 8Johns Hopkins Univ. Sch. of Med., Baltimore, MD, USA; 9Mt. Sinai Sch. of Med., New York, NY, USA; and 10Univ. of Liverpool, UK |
| 11:30 am 137 | Tolerance and Potent Anti-HIV-1 Activity of Reverset following 10 Days of Mono-therapy in Treatment-naïve Individuals R L Murphy*1, D Schürmann2, A Beard3, L Cartee3, R F Schinazi4, and M J Otto3 1Northwestern Univ., Chicago, IL, USA; 2Charité Univ. Hosp., Berlin, Germany; 3Pharmasset, Inc., Tucker, GA, USA; and 4Emory Univ. Sch. Med. and VA Med. Ctr., Atlanta, GA, USA |
| 11:45 am 138 | Pharmacological Evaluation of a Dual Deoxycytidine Analogue Combination: 3TC and SPD754 R Bethell*1,4, J Adams1,2, J De Muys3,4, J Lippens3,4, A Richard4, B Hamelin4, C Ren4, P Collins4, C Struthers-Semple3, T Holdich3, and J Sawyer2 1PharmaRes., Morrisville, NC, USA; 2Prism Ideas Ltd., Nantwich, UK; 3Shire Pharm. Devt., Basingstoke, UK; and 4Shire Biochem Inc., Laval, Canada |
| 12:00 pm 139 | Single and Multiple Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Receptor Binding of GW873140, a Novel CCR5 Receptor Antagonist, in Healthy Subjects J Demarest1, K Adkison1, S Sparks1, A Shachoy-Clark1, K Schell1,2, S Reddy1, L Fang1, K O'Mara1, S Shibayama3, and S Piscitelli*1 1GlaxoSmithKline, Research Triangle Park, NC, USA; 2Univ. of Wisconsin, Madison, USA; and 3ONO Pharm. Ltd., Osaka, Japan |
| 12:15 pm 140LB | SCH D: Antiviral Activity of a CCR5 Receptor Antagonist D Schurmann1, R Rouzier2, R Nougarede2, J Reynes3, G Fatkenheuer4, F Raffi5, C Michelet6, A Tarral7, C Hoffmann8, J Kiunke8, H Sprenger9, J vanLier10, A Sansone11, M Jackson11, and M Laughlin*11 1Clin. Res./Charite Hosp., Berlin, Germany; 2CentreCap, Montpellier, France; 3CHU Gui De Chauliac, Montpellier, France; 4Univ. of Cologne, Germany; 5Nantes Med. Univ., France; 6Univ. Hosp. of Rennes, France; 7Biotrial, Rennes, France; 8Univ. of Kiel, Germany; 9Univ. Hosp. Groningen, The Netherlands; 10PharmaBioResearchGroup BV, Groningen, The Netherlands; and 11SPRI, Kenilworth, NJ, USA |
| 12:30 pm 141 | Antiviral Activity, Safety, and Tolerability of a Novel, Oral Small-molecule HIV-1 Attachment Inhibitor, BMS-488043, in HIV-1-infected Subjects
a Novel, Oral Small-Molecule HIV-1 Attachment Inhibitor,
BMS-488043, in HIV-1-Infected Subjects G Hanna*1, J Lalezari2, J Hellinger3, D Wohl4, T Masterson1, W Fiske1, J Kadow1, P Lin1, M Giordano1, R Colonno1, and D Grasela1 1Bristol-Myers Squibb Co., Princeton, NJ, USA; 2Quest Clin. Res., San Francisco, CA, USA; 3Community Res. Initiative of New England, Boston, MA, USA; and 4Univ. of North Carolina at Chapel Hill, USA |